Catalent (NYSE:CTLT) Price Target Lowered to $55.00 at Deutsche Bank Aktiengesellschaft

Posted by Defense World Staff on May 10th, 2023

Catalent (NYSE:CTLT – Get Rating) had its price objective trimmed by Deutsche Bank Aktiengesellschaft from $72.00 to $55.00 in a research report released on Tuesday, The Fly reports.

A number of other research analysts have also commented on the stock. William Blair lowered shares of Catalent from an outperform rating to a market perform rating in a research report on Friday, April 14th. Barclays lowered their target price on shares of Catalent from $70.00 to $40.00 in a research note on Monday, April 17th. Royal Bank of Canada lowered their target price on shares of Catalent from $58.00 to $41.00 in a research note on Monday. Robert W. Baird cut shares of Catalent from an outperform rating to a neutral rating and lowered their target price for the company from $82.00 to $53.00 in a research note on Monday, April 17th. Finally, StockNews.com raised shares of Catalent to a sell rating in a research note on Saturday, April 15th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of Hold and a consensus price target of $77.40.

Catalent Stock Down 1.2 %

Shares of CTLT opened at $35.04 on Tuesday. The company has a 50-day simple moving average of $58.96 and a 200-day simple moving average of $54.76. The firm has a market capitalization of $6.31 billion, a P/E ratio of 15.50, a P/E/G ratio of 2.38 and a beta of 1.17. The company has a debt-to-equity ratio of 0.86, a quick ratio of 1.38 and a current ratio of 1.91. Catalent has a 52 week low of $33.05 and a 52 week high of $115.33.

Catalent (NYSE:CTLT – Get Rating) last announced its quarterly earnings data on Tuesday, February 7th. The company reported $0.62 EPS for the quarter, missing analysts’ consensus estimates of $0.64 by ($0.02). The company had revenue of $1.15 billion for the quarter, compared to analyst estimates of $1.12 billion. Catalent had a net margin of 8.62% and a return on equity of 11.40%. On average, equities research analysts expect that Catalent will post 2.6 earnings per share for the current year.

Insiders Place Their Bets

In other news, SVP Mario Gargiulo sold 678 shares of the company’s stock in a transaction that occurred on Monday, May 1st. The shares were sold at an average price of $49.86, for a total transaction of $33,805.08. Following the transaction, the senior vice president now directly owns 5,676 shares in the company, valued at $283,005.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, SVP Mario Gargiulo sold 678 shares of the company’s stock in a transaction that occurred on Monday, May 1st. The shares were sold at an average price of $49.86, for a total transaction of $33,805.08. Following the transaction, the senior vice president now directly owns 5,676 shares in the company, valued at $283,005.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Manja Boerman sold 1,446 shares of the company’s stock in a transaction that occurred on Monday, May 1st. The stock was sold at an average price of $49.86, for a total transaction of $72,097.56. Following the transaction, the insider now owns 14,414 shares in the company, valued at $718,682.04. The disclosure for this sale can be found here. Insiders own 0.58% of the company’s stock.

Hedge Funds Weigh In On Catalent

Several large investors have recently bought and sold shares of CTLT. Veritas Asset Management LLP lifted its holdings in Catalent by 60.5% in the fourth quarter. Veritas Asset Management LLP now owns 11,169,815 shares of the company’s stock valued at $502,753,000 after buying an additional 4,212,040 shares during the period. Artisan Partners Limited Partnership lifted its holdings in Catalent by 33.6% in the fourth quarter. Artisan Partners Limited Partnership now owns 7,842,308 shares of the company’s stock valued at $352,982,000 after buying an additional 1,973,505 shares during the period. Eminence Capital LP lifted its holdings in Catalent by 151.3% in the fourth quarter. Eminence Capital LP now owns 2,547,332 shares of the company’s stock valued at $114,655,000 after buying an additional 1,533,669 shares during the period. Norges Bank acquired a new position in Catalent in the fourth quarter valued at approximately $65,774,000. Finally, Maverick Capital Ltd. acquired a new position in Catalent in the fourth quarter valued at approximately $63,088,000. 99.38% of the stock is currently owned by institutional investors and hedge funds.

About Catalent

(Get Rating)

Catalent, Inc is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services.